59 results
6-K
EX-99.1
OBSVF
ObsEva SA
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
dedicated to women and their health. Theramex supports women at every stage of their lives by providing a broad portfolio of innovative and established … on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products” and “serving society through our
6-K
EX-99.1
OBSVF
ObsEva SA
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Theramex’s commitment is to listen … pharmaceutical company based on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products
6-K
EX-99.1
OBSVF
ObsEva SA
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Our commitment is to listen to and understand … through high-quality, innovative pharmaceutical products” and “serving society through our employees.” As a strong R&D-oriented corporation
6-K
EX-99.1
OBSVF
ObsEva SA
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
women at every stage of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause … on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products” and “serving society through our employees
6-K
EX-99.1
OBSVF
ObsEva SA
4 Feb 22
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral
4:37pm
pharmaceutical company based on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products” and “serving … society through our employees.” As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide
6-K
j95zu980350msrmp7cj
6 Jul 18
Current report (foreign)
7:42am
6-K
EX-99.1
gu8x1vtnlmta7dj2qx24
22 Mar 22
Current report (foreign)
7:28am
6-K
EX-99.1
640 32hebyurg6l6ah
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
EX-99.2
w9dxycdwxe0oqygh 4s
7 Nov 19
Current report (foreign)
9:11am
6-K
EX-99.1
140b5b
1 Jul 20
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
6:15am
6-K
EX-99.3
a61yspcw
7 Nov 19
Current report (foreign)
9:11am
6-K
EX-99.1
oc7kab9
22 Apr 21
ObsEva Annual General Meeting 2021
6:31am
6-K
EX-99.1
vrivjncs5qvrzzhsv
27 Jul 21
Current report (foreign)
6:12am
6-K
EX-99.3
kh313o2rsqbkf19 9u
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
6-K
EX-99.1
pmbadb66d8jias2c 58
5 Mar 21
ObsEva Announces Year End 2020 Financial Results
7:21am
6-K
EX-99.1
04csf7 ma
10 Feb 21
ObsEva Provides Business Outlook for 2021
6:10am
6-K
EX-99.1
ivgfj
16 May 18
Index to Unaudited Consolidated Interim Financial Statements
4:56pm
6-K
fg3z7 dro9
15 Jan 20
Current report (foreign)
8:35pm
6-K
EX-99.1
3z38l33u
9 May 19
Index to Unaudited Condensed Consolidated Financial Statements
6:05am
6-K
EX-99.1
1igb4 y4lysae9ft5jw3
8 Nov 18
Index to Unaudited Condensed Consolidated Financial Statements
9:28am